Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3005
Abstract: 3005Background: SHP2 transduces signals from activated receptor tyrosine kinases to downstream pathways including MAPK. TNO155 is a selective, allosteric, oral inhibitor of SHP2. Methods: CTNO155X2... read more here.
Keywords: tno155; shp2; dose finding; results dose ... See more keywords